26 June 2026
26 June 2026
The first patient was treated at Monash Health in Clayton, Victoria, Australia, with other trial sites planned in the near future.
Recordati will handle regulatory filings and commercial operations ex-US, including supporting early access initiatives.
RQ Bio’s lead asset, RQB01, is currently in IND-enabling studies.
Primary objectives involve assessing the tolerability, pharmacokinetics and safety of VK3019.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
